Variation in the Interleukin-6 Receptor Gene Associates With Type 2 Diabetes in Danish Whites
Article Figures & Tables
Tables
- TABLE 1
The clinical characteristics of the study groups enrolled in the type 2 diabetes case-control study
N n (men/women) Age (years) Age at clinical diagnosis (years) BMI (kg/m2) HbA1c (%) Type 2 diabetic patients 1,349 Type 2 diabetic patients from the Inter99 cohort 324 (202/122) 51.1 ± 7.1 49.2 ± 8.3 30.4 ± 5.6 7.0 ± 1.6 Type 2 diabetic patients from Steno Diabetes Center 1,025 (617/408) 58.8 ± 10.7 52.7 ± 10.4 29.5 ± 5.2 8.0 ± 1.6 NGT subjects 4,596 NGT subjects from the Inter99 cohort 4,251 (1,972/2,279) 45.2 ± 7.8 — 25.5 ± 4.0 5.8 ± 0.4 Elderly NGT subjects 345 (164/181) 62.4 ± 4.9 — 26.3 ± 3.6 6.1 ± 0.4 NGT subjects matched on age and sex with type 2 diabetic patients 1,365 1,365 (794/571) 57.0 ± 5.0 — 26.1 ± 3.9 5.9 ± 0.4 Data are means ± SD.
- TABLE 2
Genotype distribution and allele frequencies of the Asp358Ala polymorphism of the IL6R in 1,349 type 2 diabetic patients and in 4,596 glucose-tolerant subjects
Type 2 diabetes NGT P Precessive Pdominant OR (95% CI) n (men/women) 1,349 (819/530) 4,596 (2,136/2,460) Asp/Asp 509 (37.7%) 1612 (35.1%) Asp/Ala 647 (48.0%) 2180 (47.4%) Ala/Ala 193 (14.3%) 804 (17.5%) 0.019 0.008 0.068 Ala allele 38.3 (36.5–40.1) 41.2 (40.2–42.2) 0.007 Asp/Asp vs. Ala/Ala 1.38 (1.09–1.71) Asp/Asp vs. Asp/Ala 1.08 (0.93–1.26) Asp/Ala vs. Ala/Ala 1.25 (1.02–1.53) Data are number of subjects with each genotype (% of each group) and % (95% CI) unless otherwise indicated. P comparing case versus control subjects in a codominant model, recessive model (Precessive), and dominant model (Pdominant).
- TABLE 3
Clinical and biochemical data of 4,251 middle-aged glucose tolerant white subjects from the Inter99 cohort when classified in accordance to their genotype of the Asp358Ala polymorphism of IL6R
Asp/Asp Asp/Ala Ala/Ala P* Precessive† Pdominant‡ n (men/women) 1,495 (682/813) 2,013 (942/1,071) 743 (348/395) Age (years) 45 ± 8 45 ± 8 45 ± 8 BMI (kg/m2) 25.6 ± 4.1 25.5 ± 4.0 25.4 ± 4.0 NS NS NS Waist-to-hip ratio 0.84 ± 0.09 0.84 ± 0.08 0.84 ± 0.08 NS NS NS Plasma glucose at 0 min (mmol/l) 5.3 ± 0.4 5.3 ± 0.4 5.3 ± 0.4 NS NS NS Plasma glucose at 120 min (mmol/l) 5.5 ± 1.1 5.5 ± 1.1 5.4 ± 1.1 NS NS NS Incremental AUC glucose (mmol/l) 181 ± 104 184 ± 99 179 ± 98 NS NS NS Serum insulin at 0 min (pmol/l) 38 ± 24 37 ± 23 37 ± 23 NS NS NS Serum insulin at 120 min (pmol/l) 167 ± 121 167 ± 133 169 ± 139 NS NS NS Incremental AUC insulin (pmol/l) 21,151 ± 13,358 20,878 ± 13,288 20,782 ± 12,811 NS NS NS Insulinogenic index insulin 31 ± 21 31 ± 19 31 ± 18 NS NS NS HOMA-IR 9.1 ± 5.7 8.8 ± 5.6 8.8 ± 5.7 NS NS NS Serum cholesterol (mmol/l) 5.4 ± 1.0 5.4 ± 1.0 5.4 ± 1.0 NS NS NS Serum HDL cholesterol (mmol/l) 1.45 ± 0.40 1.47 ± 0.40 1.47 ± 0.40 NS NS NS Serum triglycerides (mmol/l) 1.16 ± 0.70 1.18 ± 0.80 1.21 ± 1.53 NS NS NS Data are means ± SD.
- *
* Comparing Asp/Asp, Asp/Ala, and Ala/Ala;
- †
† comparing Asp/Asp and Asp/Ala with Ala/Ala; and
- ‡
‡ comparing Asp/Asp with Asp/Ala and Ala/Ala, all after adjustment for age, BMI, and sex. AUC, area under the curve; HOMA-IR, homeostasis model assessment of insulin resistance index; NS, not significant.
In this Issue
